Citius Oncology (CTOR) Change in Receivables (2025 - 2026)

Citius Oncology (CTOR) recorded quarterly Change in Receivables of -$3.0 million in Q1 2026, down 173.35% quarter-over-quarter from $4.0 million in Q4 2025.

Citius Oncology (CTOR) Change in Receivables (2025 - 2026) Analysis & Trends

Citius Oncology's Change in Receivables history runs 2 years deep, the most recent figure standing at -$3.0 million for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Receivables (Qtr)
1 Teva Pharmaceutical Industries 38.34 Bn 34.60 Bn 1.97 Bn -78.00 Mn
2 Zoetis 33.27 Bn 31.33 Bn 1.62 Bn 106.00 Mn
3 United Therapeutics 23.75 Bn 21.60 Bn 648.10 Mn -38.20 Mn
4 Aurora Cannabis 17.11 Bn 17.03 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.37 Bn 15.05 Bn 800.70 Mn 81.40 Mn
6 Elanco Animal Health 11.78 Bn 11.35 Bn 785.00 Mn -
7 Alkermes 7.05 Bn 6.54 Bn -116.06 Mn 23.22 Mn
8 Lantheus Holdings 6.49 Bn 5.99 Bn 230.92 Mn 2.23 Mn
9 Hims & Hers Health 6.19 Bn 5.44 Bn 396.79 Mn 116.25 Mn
10 Citius Oncology 75.12 Mn 72.49 Mn 1.34 Mn -2.97 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -2.97 Mn
Mar 31, 2026 -2.97 Mn
Dec 31, 2025 4.05 Mn
Dec 31, 2025 4.05 Mn